Materialise to Expand Reach in Fast-growing Brazilian Market with Strategic Investment in Engimplan LTDA
August 01 2019 - 8:30AM
Business Wire
Investment will allow Materialise to bring benefits of
personalized 3D printed implants to Brazil
Materialise (NASDAQ:MTLS), a global leader in 3D printing
solutions, today announced a strategic investment in Engimplan, a
Brazil-based manufacturer of orthopedic and cranio-maxillofacial
(CMF) implants and instruments. The combination of Materialise’s
expertise in 3D printed medical solutions with Engimplan’s
innovative product portfolio will help to accelerate the
introduction of 3D printed, personalized implants and instruments
in the Brazilian market.
Materialise has signed an agreement to acquire a 75% stake in
Engimplan through a combined acquisition of existing and new shares
via its Brazilian subsidiary Engimplan Holding Ltda. Closing of the
transaction is expected to take place early August. As part of the
transaction, Materialise will gain access to Engimplan’s local
production facility; expand Engimplan’s portfolio with its 3D
printed implants and expertise; and enter the company’s existing
partner and distribution network in Brazil.
Patient-specific implants offer unique benefits for the
treatment of orthopedic and cranial trauma and reconstruction. 3D
printing provides additional benefits by allowing the development
of truly personalized implants that take into account the patient’s
unique anatomy.
“Surgical planning and 3D printing are increasingly adopted by
orthopedic and CMF surgeons, as they understand the positive impact
of personalized implants and patient-specific solutions on surgical
outcomes”, says Brigitte de Vet, Vice President and General Manager
of Materialise Medical. “With this investment, we will expand our
medical product and service portfolio, confirming our commitment to
strengthen our position and grow our global presence in the medical
industry.”
Established in 1992, Engimplan develops, manufactures and sells
orthopedic and CMF implants and instruments in the Brazilian
market. Today, its product offering consists of standard solutions
and patient-specific CMF implants that are complementary to
Materialise’s product portfolio. With Materialise’s in-depth
knowledge of 3D printing and experience in developing certified,
personalized medical solutions, Engimplan will be able to further
expand its innovative product suite.
Materialise has nearly three decades of experience in developing
certified medical solutions that help researchers, engineers and
clinicians achieve the desired patient outcomes. The company
develops 3D imaging and printing solutions that help surgeons more
accurately plan and execute operations. In addition, Materialise
develops 3D printed, personalized implants and instruments that
enable improved surgical and esthetic outcomes, improving patients’
lives.
“This investment by Materialise sends a strong signal to our
customers and the industry that we remain committed to developing
our innovative solutions that improve the lives of many people, and
that we have the confidence and support of a pioneer and global
leader in 3D printing”, says José Tadeu Leme, CEO of Engimplan.
“Together, we can introduce new levels of innovation in the
development of personalized implants in Brazil.”
Materialise will provide more details about the transaction
during its Q2 earnings call on August 6, 2019.
A blog by Brigitte de Vet, Vice President and General Manager of
Materialise Medical, is available at
https://www.materialise.com/en/blog/materialise-expands-reach-in-brazilian-market
About Materialise Materialise incorporates nearly three
decades of 3D printing experience into a range of software
solutions and 3D printing services, which together form the
backbone of the 3D printing industry. Materialise’s open and
flexible solutions enable players in a wide variety of industries,
including healthcare, automotive, aerospace, art and design, and
consumer goods, to build innovative 3D printing applications that
aim to make the world a better and healthier place. Headquartered
in Belgium, with branches worldwide, Materialise combines the
largest group of software developers in the industry with one of
the largest 3D printing facilities in the world. For additional
information, please visit: www.materialise.com.
About Engimplan With almost three decades of expertise in
the production of implants and orthopedic instruments, Engimplan
provides its clients and surgeons with a complete range of
prostheses with high levels of value, bringing about improvements
in the lives of patients and generating sustainable benefits. Aware
of its role in society and its mission as a purveyor of solutions
for the medical field, Engimplan is in the leading vanguard of new
product development, pioneering the personalization of implants,
tailored to each patient and always taking into consideration their
health and their full and continued participation in life. In 2018,
Engimplan realized revenue of €6.2 million with an EBITDA margin of
39%.*
Cautionary Statement on Forward-Looking Statements Some
of the statements in this press release are "forward-looking" and
are made pursuant to the safe harbor provision of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include statements relating to, among other things, the
timing and benefits of the Engimplan investment, our planned
commercialization efforts and regulatory approvals of our
technologies as well as the success thereof and our research and
development projects. These forward-looking statements are based
upon the expectations of management under current assumptions at
the time of this press release. We caution you that forward-looking
statements are not guarantees of future performance and involve
known and unknown risks, uncertainties and other factors that are
in some cases beyond our control that may cause our actual results
to differ materially from our expectations. We are providing this
information as of the date of this press release and do not
undertake any obligation to update any forward-looking statements
contained in this presentation as a result of new information,
future events or otherwise, unless we have obligations under the
federal securities laws to update and disclose material
developments related to previously disclosed information.
* As reported under Brazilian GAAP; amounts have been converted
from Brazilian real (BRL) into euro according to the July 2019
average ECB reference exchange rates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190801005510/en/
Press: Materialise Kristof Sehmke Email:
Kristof.sehmke@materialise.be Or press@materialise.com Twitter:
@MaterialiseNV Visit: www.materialise.com
Materialise NV (NASDAQ:MTLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Materialise NV (NASDAQ:MTLS)
Historical Stock Chart
From Apr 2023 to Apr 2024